Change PGIC

Related by string. * changes . change . Changes . CHANGES . Change - [001] . CHANGE . Change - [003] . Change - [005] : Last Change Pct . Proposed Rule Change . Climate Change Secretariat . Climate Change UNFCCC . Climate Change IPCC . Climate Change DECC . Climate Change Shyam Saran . Average Directional Change ADX / : Corporation PGIC . Corporation NASDAQ PGIC . Nasdaq PGIC . NASDAQ PGIC . PGIC * *

Related by context. Frequent words. (Click for all words.) 59 Montgomery Asberg Depression 58 Secondary endpoints include 58 plus prednisone 57 Solid Tumors 57 pertuzumab 56 prospectively defined 56 nab paclitaxel 56 relapsing multiple sclerosis 56 Group ECOG 56 active comparator 56 RECIST criteria 55 Negative Syndrome 55 PANSS 55 ord = + krdDartOrd 55 NLX P# 55 Response Evaluation Criteria 55 Secondary endpoints 55 Secondary endpoints included 55 Alzheimer Disease Assessment 55 pharmacodynamic effects 55 mucosal healing 54 Arch Pediatr Adolesc Med 54 plus dexamethasone 54 PREZISTA r 54 placebo controlled clinical 54 forodesine 53 annualized relapse 53 nonrandomized 53 cytogenetic response 53 Traficet EN 53 relapsed refractory multiple myeloma 53 0 document.write 53 plus methotrexate 53 Randomized controlled 53 adjuvant chemotherapy 53 Currency Majors Technical 53 #mg/day [001] 53 neoadjuvant chemotherapy 53 irbesartan 53 hospitals physicians homecare 53 platelet reactivity 53 HER2 positive metastatic breast 52 neoadjuvant 52 FOLFOX 52 FOLFIRI 52 mso tstyle rowband size 52 PRECiSE 52 Thrombolysis 52 tocilizumab 52 registrational trial 52 XELOX 52 HRQOL 52 Gynecologic Oncology Group 52 ACRIN 52 symptom severity 52 Pegasys ® 52 Engerix B 52 HERmark 52 Radiation Therapy Oncology 52 ADAS cog 52 elotuzumab 52 sustained virologic response 52 Global Impression 51 achieved statistical significance 51 mso tstyle colband size 51 Retisert 51 CCX# 51 GSK# [001] 51 surrogate endpoint 51 multicenter Phase 51 HbA1c levels 51 docetaxel chemotherapy 51 Recurrence Score 51 randomized Phase III 51 analgesic efficacy 51 mg BID 51 adjuvant radiation 51 label multicenter 51 mycophenolate mofetil 51 seroprotection 51 prospective multicenter 51 PTNS 51 phase IIb clinical 51 PRADAXA 51 multiple myeloma MM 51 Arch Intern Med 51 Taxotere ® 51 Expanded Disability Status 51 TORISEL 51 Clinical Outcomes 51 Adalimumab 51 carboplatin paclitaxel 51 undetectable HCV RNA 50 adecatumumab 50 ACR# response 50 celgosivir 50 rEEG 50 Taxus Stent 50 Arch Neurol 50 Fludara 50 RTOG

Back to home page